A Double-blind, Randomized, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088, in Healthy Volunteers
Latest Information Update: 28 Jan 2022
Price :
$35 *
At a glance
- Drugs Icerguastat (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions; First in man
- Sponsors InFlectis BioScience
- 08 Aug 2018 New trial record
- 22 May 2018 According to InFlectis BioScience media release,First results from the study are expected in the first half of 2019. This study will provide the safety data necessary for Phase 2 studies in Charcot-Marie-Tooth (CMT) patients that are expected to begin end of 2019.